Skip to main content
Premium Trial:

Request an Annual Quote

Vala Sciences Enters Market with Cell Image-Based Reagents, Analysis Software Tools

NEW YORK, Feb. 16 (GenomeWeb News) - Vala Sciences will now begin to sell cell image-based reagents and analysis software tools for academic, pharmaceutical, and biotech scientists, the company said today.


The LaJolla, Calif.-based start-up, less than a year old, also announced that it is starting off with $3.5 million in funding from the National Institutes of Health, the California Technology Investment Partnership Program, and private individual investors.


Vala's core team, headed by CEO Jeffrey Price, said that its automated technology would save researchers weeks of time when analyzing images attained by fluorescence-based microscopy. Price formerly developed software for microscopy analysis for Q3DM.


According to Vala, collaborations have already been initiated with the Chemical Genomics Research Consortium of the Gulf Coast Consortia, The Burnham Institute, Regenemed, and the University of Florida for a variety of projects.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.